Airway Therapeutics, a Sharonville-based biopharmaceutical startup, has logged another key milestone in its path toward commercialization. The company, which is developing new interventions for acute and chronic lung diseases, dosed its first patient this month in a new clinical trial aimed at patients severely impacted by Covid-19.
The accomplishment is a huge step for the company, CEO Dr. Marc Salzberg told me, and comes as infections from the virus increase nationwide. It serves as a new potential treatment option for patients in desperate need, he said.
